Trastuzumab biosimilar

BIOLOGICAL2 trials

Sponsors

Jin-Hee Ahn, Merck Sharp & Dohme LLC

Conditions

Breast CancerBreast NeoplasmsHER-2 Gene AmplificationHER-2 Protein Overexpression

Phase 1

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

RecruitingNCT06686394

Merck Sharp & Dohme LLCBreast Cancer, Breast Neoplasms

Start: 2025-02-26End: 2030-04-18Target: 81Updated: 2026-02-13

Phase 2

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Jin-Hee AhnHER-2 Gene Amplification, HER-2 Protein Overexpression

Start: 2019-12-30End: 2019-12-30Target: 42Updated: 2020-01-02

Related Papers

Abstract PS5-12-23: Herthena-breast01: a phase 1b/2, multicenter, open-label, dose-finding study to evaluate the safety and antitumor activity of patritumab deruxtecan (HER3-DXd) in HER2+ unresectable locally advanced or metastatic breast cancer

Clinical Cancer Research2026-02-17

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Nature Medicine2025-05-3011 citations